MX2013008269A - Composicion farmaceutica que comprende derivados de piridona. - Google Patents

Composicion farmaceutica que comprende derivados de piridona.

Info

Publication number
MX2013008269A
MX2013008269A MX2013008269A MX2013008269A MX2013008269A MX 2013008269 A MX2013008269 A MX 2013008269A MX 2013008269 A MX2013008269 A MX 2013008269A MX 2013008269 A MX2013008269 A MX 2013008269A MX 2013008269 A MX2013008269 A MX 2013008269A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pyridone derivatives
solvate
isomer
hydrate
Prior art date
Application number
MX2013008269A
Other languages
English (en)
Other versions
MX351180B (es
Inventor
Cheol Young Maeng
Young Koo Jang
Su Bong Cha
Hye Won Shin
Chan Mi Joung
Eun Jung Yi
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2013008269A publication Critical patent/MX2013008269A/es
Publication of MX351180B publication Critical patent/MX351180B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

Un compuesto derivado de piridona y su sal, isómero, solvato o hidrato farmacéuticamente aceptable y una composición farmacéutica preventiva o terapéutica para trastornos cognitivos que incluye el compuesto derivado piridona o su sal, isómero, solvato o hidrato farmacéuticamente aceptable.
MX2013008269A 2011-01-28 2012-01-30 Composicion farmaceutica que comprende derivados de piridona. MX351180B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110008962 2011-01-28
PCT/KR2012/000652 WO2012102583A1 (en) 2011-01-28 2012-01-30 Pharmaceutical composition comprising pyridone derivatives

Publications (2)

Publication Number Publication Date
MX2013008269A true MX2013008269A (es) 2013-08-12
MX351180B MX351180B (es) 2017-10-04

Family

ID=46581020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008269A MX351180B (es) 2011-01-28 2012-01-30 Composicion farmaceutica que comprende derivados de piridona.

Country Status (15)

Country Link
US (7) US8952165B2 (es)
EP (1) EP2668185B1 (es)
JP (1) JP5859571B2 (es)
KR (2) KR101928505B1 (es)
CN (1) CN103339131B (es)
AU (1) AU2012209596B2 (es)
CA (1) CA2824679C (es)
CL (1) CL2013002097A1 (es)
ES (1) ES2613728T3 (es)
HK (1) HK1187336A1 (es)
MX (1) MX351180B (es)
PL (1) PL2668185T3 (es)
RU (1) RU2585287C2 (es)
WO (1) WO2012102583A1 (es)
ZA (1) ZA201305227B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925971B1 (ko) * 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
CN109293507B (zh) * 2018-10-12 2020-12-18 河北科技大学 4-甲氧基甲烯基-2-烯戊二酸二甲酯的合成方法及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404138A (en) * 1982-06-22 1983-09-13 Warner-Lambert Company 3-[2-(Azabicyclo) ethyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6492385B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
PL362989A1 (en) * 2000-12-22 2004-11-15 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
BR0212101A (pt) * 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
EP1478646A1 (en) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
EP1515967B1 (de) * 2002-06-10 2006-11-02 Bayer HealthCare AG 2-heteroarylcarbonsäureamide
US7176198B2 (en) * 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
EP1543000B1 (en) * 2002-09-25 2013-03-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
CA2550847A1 (en) * 2003-12-22 2005-07-07 Glen Ernst Nicotinic acetylcholine receptor ligands
JP4995075B2 (ja) * 2004-03-25 2012-08-08 メモリー・ファーマシューティカルズ・コーポレイション インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用
WO2006069097A2 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
EP2344636B1 (en) * 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
KR101925971B1 (ko) * 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
US8952165B2 (en) 2015-02-10
WO2012102583A1 (en) 2012-08-02
US20230390259A1 (en) 2023-12-07
KR101928505B1 (ko) 2018-12-12
EP2668185A4 (en) 2014-04-02
AU2012209596A1 (en) 2013-08-01
HK1187336A1 (en) 2014-04-04
AU2012209596B2 (en) 2017-03-02
KR20120087853A (ko) 2012-08-07
EP2668185A1 (en) 2013-12-04
US10456385B2 (en) 2019-10-29
US9987259B2 (en) 2018-06-05
US20130296340A1 (en) 2013-11-07
CN103339131B (zh) 2015-05-13
US20200000782A1 (en) 2020-01-02
CL2013002097A1 (es) 2013-10-04
US20210085658A1 (en) 2021-03-25
JP2014503600A (ja) 2014-02-13
CA2824679C (en) 2018-12-04
KR102034305B1 (ko) 2019-10-18
US20150111901A1 (en) 2015-04-23
ZA201305227B (en) 2014-03-26
JP5859571B2 (ja) 2016-02-10
RU2013138218A (ru) 2015-03-10
ES2613728T3 (es) 2017-05-25
US20180263965A1 (en) 2018-09-20
CN103339131A (zh) 2013-10-02
PL2668185T3 (pl) 2017-05-31
KR20180133361A (ko) 2018-12-14
MX351180B (es) 2017-10-04
BR112013018781A2 (pt) 2016-10-25
US9271976B2 (en) 2016-03-01
US20160166552A1 (en) 2016-06-16
EP2668185B1 (en) 2016-11-23
CA2824679A1 (en) 2012-08-02
RU2585287C2 (ru) 2016-05-27

Similar Documents

Publication Publication Date Title
MX2021005214A (es) Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol.
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
WO2013163244A8 (en) Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12016502246B1 (en) Carboxamide derivatives
MX2016014946A (es) Derivados de carboxamida.
MX351180B (es) Composicion farmaceutica que comprende derivados de piridona.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
HK1243351A1 (zh) 一種含有吡啶並嘧啶類衍生物或其可藥用鹽的藥物組合物
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
WO2012169863A3 (en) 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
PH12016502247A1 (en) Carboxamide derivatives
WO2013035997A3 (en) Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt

Legal Events

Date Code Title Description
FG Grant or registration